Literature DB >> 35361894

CAR T cells show promise in the frontline for high-risk LBCL.

David Killock1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35361894     DOI： 10.1038/s41571-022-00628-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.

Authors:  Sattva S Neelapu; Michael Dickinson; Javier Munoz; Matthew L Ulrickson; Catherine Thieblemont; Olalekan O Oluwole; Alex F Herrera; Chaitra S Ujjani; Yi Lin; Peter A Riedell; Natasha Kekre; Sven de Vos; Christine Lui; Francesca Milletti; Jinghui Dong; Hairong Xu; Julio C Chavez
Journal:  Nat Med       Date:  2022-03-21       Impact factor: 87.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.